drugset / Trial / NCT01134055

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

NCT01134055

Phase 2 Completed 510 enrolled GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.

Timeline

Start
2010-06-01
Primary completion
2012-10-01
Completion
2012-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Pazopanib Small molecule 5 mg/ml Other
Subject Pazopanib Small molecule 10 mg/ml Other
Comparator Ranibizumab Monoclonal antibody Intravitreal